Abstract
AimTo summarize the follow-up of children who underwent orthotopic heart transplantation (HTx) in the Center of Cardiovascular and Transplantation Surgery in Brno during the past 17 years. Patients and methodsBetween May 1995 and October 2012, 42 children aged 2 months–17.5 years were listed for HTx, of these 26 underwent HTx later. ResultsOf 42 children listed for HTx, 12 died, 26 underwent HTx, 3 were excluded because of improved clinical status, and 1 is waiting for HTx. Five children died early after the transplantation, one patient died 6.5 years after HTx. The 1-year, 5-years and 10-years post-transplantation survival rates are 81%, 81%, and 76.9%, respectively. One patient underwent re-transplantation 11.5 years after HTx because of coronary artery disease affecting the graft. Long-term follow-up data are available for 21 children surviving 1.6–17.4 years (mean 8.7±5.3 years). The most common morbidities were hypertension and mild chronic kidney disease (CKD 2). Pneumonia was the most common infectious complication requiring hospitalization. EBV infection with subsequent development of post-transplant lymphoproliferative disorder (PTLD) was a severe late complication in two patients (diagnosed 8 and 15 years after transplantation). The increase in incidence of coronary artery disease during the second decade post-HTx (affecting 7.7% patients after 5 years and 42.8% patients after 10 years) leads to a significant increase in the morbidity of pediatric patients surviving more than 10 years after transplantation. ConclusionHeart transplantation currently represents an effective treatment of terminal heart failure in children. Improving outcomes of pediatric HTx mainly reflect the drop in early mortality. The main causes of late morbidity and mortality of children after HTx are the increase in incidence of coronary artery disease and malignant diseases (PTLD). Our results of long-term follow-up of children after heart transplantation are consistent with published data from other centers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.